



- 1 Article
- Immunogenicity following two doses of BBIBP-CorV vaccine
- and a third booster dose with viral vector and mRNA
- 4 COVID-19 vaccines against delta and omicron variants in prime
- 5 immunized adults with two doses of BBIBP-CorV vaccine
- 6 Jira Chansaenroj¹, Nungruthai Suntronwong¹, Sitthichai Kanokudom^{1,2}, Suvichada Assawakosri^{1,2}, Ritthideach
- 7 Yorsaeng¹, Preeyaporn Vichaiwattana¹, Sirapa Klinfueng¹, Lakana Wongsrisang¹, Donchida Srimuan¹, Thaksaporn
- 8 Thatsanatorn¹, Thanunrat Thongmee¹, Chompoonut Auphimai¹, Pornjarim Nilyanimit¹, Nasamon Wanlapakorn^{1,3},
- 9 Natthinee Sudhinaraset¹, Yong Poovorawan^{1, 4*}

11 12

13 14

15 16

17 18

19 20 21

222324

25

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. Vaccines 2022, 1027 x. https://doi.org/10.3390/xxxxx 28

Academic Editor: Firstname 29
Lastname 30
Received: date 31
Accepted: date 32
Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and inst²4 tutional affiliations.



Copyright: © 2022 by the author§6 Submitted for possible open access publication under the terms and conditions of the Creative Common®7 Attribution (CC BY) licens§8 (https://creativecommons.org/license s/by/4.0/).

40

Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; e-mail@e-mail.com

- Osteoarthritis and Musculoskeleton Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; e-mail@e-mail.com
- Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University; e-mail@e-mail.com
- 4 The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand; e-mail@e-mail.com
- * Correspondence: Yong.P@chula.ac.th; Tel.: +662 256 4929

Abstract: Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccinated with two doses of BBIBP-CorV vaccine and to explore the boosting effect of the different vaccine platforms in BBIBP-CorV-primed healthy adults, including viral vector vaccine (AZD122) and mRNA vaccines (BNT162b2 and mRNA-1273). The results showed that, in the BBIBP-CorV prime group, the total receptor-binding domain (RBD) immunoglobulin (Ig) and anti-RBD IgG levels waned significantly at 3 months after receiving the second dose. However, after the booster, RBD-specific binding antibody levels increased. Neutralizing antibody measured by a surrogate neutralization test showed of inhibition over 90% against the SARS-CoV-2 delta variant but less than 70% against omicron variant after the third dose on day 28. All booster vaccines could induce the total IFN-□ T-cell response. The reactogenicity was acceptable and well tolerated without serious adverse events. This study supported administration of the third dose with either viral vector or mRNA vaccine for the BBIBP-CorV-primed individuals to stimulate antibody and T cell responses.

Keywords: Third dose, Inactivated vaccine, BBIBP-CorV, viral vector vaccine, mRNA vaccine

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can result in mild to severe illness leading to hospitalization and death [1]. Currently available COVID-19 vaccines have been effective for the control and prevention of COVID-19 outbreaks. During this pandemic, many COVID-19 vaccines have been approved by the World Health Organization (WHO) for emergency use and are effective against SARS-CoV-2 in adults [2,3]. To date, inactivated vaccine candidates have been reported to be generally safe and have induced

antibody responses in adults in preclinical trials [4]. The BBIBP-CorV vaccine is a killed inactivated coronavirus vaccine prepared by β-propionolactone [5]. In May 2021, the BBIBP-CorV vaccine was the first Chinese vaccine granted approval by the WHO for emergency use. Clinical trials on the BBIBP-CorV vaccine showed that BBIBP-CorV could protect against SARS-CoV-2 infection. The average quantitative IgG anti-spike protein antibodies levels among the participants on day 18 after vaccination with the BBIBP-CorV vaccine with no previous SARS-CoV-2 infection history was 40 AU/mL [6]. The most common reported adverse reactions of the BBIBP-CorV vaccine included mild pain at the injection site, fever, and fatigue [7]. Phase 3 clinical trials between July and December 2020 in seven countries have shown that two doses of the BBIBP-CorV vaccine had an efficacy of 78.1% against symptomatic cases, 100% protection against severe disease, and a 99% rate of seroconversion [4]. However, the antibody titers waned over time and may not be adequate to protect against the omicron variant [4,8]. Therefore, the Centre for Disease Prevention and Control China recommended a booster dose for BBIBP-CorV-primed individuals to stimulate adequate protection against the newly emerged omicron variant [9].

Although the efficacy of the vaccine and the ability to induce immune responses in two-dose-immunized participants can induce robust immunity, breakthrough infection with COVID-19 has been reported worldwide [2,3]. Several studies have observed that the decline in immunity may be related to a variant virus, weakening of vaccine-induced immunity, neutralizing antibody titers, or the effectiveness of the vaccine against symptomatic illness gradually weakens over time [2,3,10,11]. A study evaluating two doses of BBIBP-CorV vaccine effectiveness against SARS-CoV-2 variants showed efficacies of 39.2% for beta, 33.9% for delta, and 11.3% for alpha variants [12]. The emergence of the SARS-CoV-2 omicron variant (B.1.1.529), with several mutations recently identified in their spike, has become the predominant variant worldwide since November 2021 [13]. In the interim statement on December 16, 2021, the WHO recommended that viral vector or mRNA vaccines can be considered third doses in those who received inactivated vaccines for initial doses [14]. Studies from the United States have found an increased estimate of vaccine effectiveness against delta and omicron variants among adults who had received a third dose of mRNA vaccine compared with unvaccinated and those who received two doses [15,16].

The immunogenicity of COVID-19 booster vaccinations has been tested in a variety of situations with various vaccines. Both heterologous and homologous third booster shots had a significantly improved immune response [17-19]. A booster vaccination has significantly increased neutralization capacity against the SARS-CoV-2 variants, thus overcoming waning immunity, circulating of the SARS-CoV-2 variants, and significantly reducing the rates of confirmed infection and severe disease [20,21]. To improve immunity and enhance resistance to variants, the third dose of COVID-19 vaccination is necessary.

Antibody and T cell responses against SARS-CoV-2 in two-dose BBIBP-CorV-primed individuals after the administration of the third dose of BNT162b2 have achieved a significant increase in both humoral and T cell-mediated immune response [22]. The immunogenicity after a booster dose with viral vector or other mRNA vaccine (mRNA1273) in BBIBP-CorV-primed individuals is limited. This study aimed to determine the kinetic response of antibodies in a cohort participant who completed the BBIBP-CorV vaccine and explore the immunogenicity of third doses with BBIBP-CorV vaccine or a heterologous booster COVID-19 vaccination using the viral vector and mRNA vaccines. The results could provide an opportunity to improve the flexibility and reliability of vaccination programs in the face of the COVID-19 pandemic.

44

45

46

47

82

83

77

84 85 86

87

92

2. Materials and Methods

2.1 Study design and population study

This study was a prospective cohort study including two groups of participants. The first group consisted of individuals who consented to receive two doses of the BBIBP-CorV vaccine (referred to as the BBIBP-CorV primed group). The second group comprised individuals primed with the two-dose BBIBP-CorV vaccine who were enrolled for the third booster (referred to as the third booster group). The binding and neutralizing antibody titer and the T cell response before and after the third dose of vaccination were evaluated. The inclusion criteria were immunocompetent individuals (age: ≥18 years) with no or well-controlled comorbidities and no previous SARS-CoV-2 infection in the medical history.

The BBIBP-CorV primed group consists of 51 participants who received the BBIBP-CorV vaccine at Synphaet Srinagarindra Hospital, Bangkok, Thailand between June, and July 2021. Blood samples from this group were collected at four time-points, day 0 (before receiving the first dose), day 30 ± 7 days (just before receiving the second dose), day 60 ± 7 days after receiving the first dose, and day 120 ± 7 after receiving the first dose.

The third booster group consisted of 144 participants who received two prime doses of BBIBP-CorV over 6 ± 1 month and were enrolled to receive the third dose at the Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University. Participants were enrolled between November and December 2021. This group was further divided into three sub-groups who were to receive the third booster dose (AZD1222, BNT162b2, or mRNA-1273). The third dose was administered according to vaccine availability. The participants and investigators were not blinded. The blood samples from this group were collected at four time points: before the third dose vaccination (day 0, baseline), and after receiving the booster dose (day 14 ± 7 days, day 28 ± 7 days, and day 90 ± 7 days).

This study protocol was approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 192/64 and 546/64). Informed consent was obtained from all subjects involved in the study prior to enrollment in the study. All volunteers were informed about the details of the study prior to its start. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines (ICH-GCP).

2.2 Study vaccines interventions

BBIBP-CorV (Vero cell) (Sinopharm, National Biotec Group Co., Beijing Institute of Biological Products, China) is an inactivated virus vaccine developed from the whole SARS-CoV-2 strain HB02. The HB02 strain is obtained by passaging and purification in Vero cells. Consequently, the entire virion is inactivated in β-propiolactone and is further absorbed with aluminum hydroxide. One dose (0.5 mL) contains 6.50 U [5]. AZD1222 (ChAdOx1-S/nCoV-19, University of Oxford/AstraZeneca, Oxford, UK) is a non-replicating chimpanzee adenovirus Oxford 1 vector vaccine presenting the SARS-CoV-2 spike protein. The virion is produced in genetically modified HEK293 cells. One dose (0.5 mL) contains 5 X 10¹⁰ infectious units [23]. BNT162b2 (Pfizer-BioNTech Inc., New York, NY, USA) and mRNA-1273 (ModernaTX Inc., Cambridge, MA, USA) are modified RNA containing lipid nanoparticles encoding the full-length spike of SARS-CoV-2, modified by two proline mutations to lock it in the prefusion conformation. One dose contains 30 and 100 μg for BNT162b2 and mRNA-1273, respectively [24,25].

After receiving the additional dose, all study participants were monitored for immunogenicity and safety.

2.3 Monitoring of adverse events

Participants were informed of the name of the vaccine and were observed adverse events for at least 30 minutes after vaccination. All participants were continuously monitored for adverse events after immunization (AEFI) within 7 days after receiving the booster dose using self-assessment records via online or paper questionnaires. The adverse events contain system reactions and local reactions. System reactions included fever, headache, myalgia, nausea, vomiting, diarrhea, joint pain, chills, and dizziness. Local reactions included pain at the injection site, swelling, and redness.

2.4 Laboratory Experiments

2.4.1 Immunoglobulin assays

All serum samples were analyzed using SARS-CoV-2 total receptor binding domain immunoglobulin (total RBD Ig) and anti-RBD IgG by using the Electrochemiluminescence Immunoassay (ECLIA) (Roche Diagnostics GmbH, Mannheim, Germany) and the chemiluminescent microparticle immunoassay (CMIA) (Abbott Diagnostics, Sligo, Ireland), respectively [26]. A total RBD Ig level of ≥ 0.8 U/mL was considered positive. The anti-RBD IgG level with a value ≥ 7.1 BAU/mL was considered positive.

2.4.2 Surrogate virus neutralization test (sVNT)

To assess SARS-CoV-2 surrogate virus neutralization, the subset of serum samples from the third booster group at all time points were also evaluated for neutralizing activity against the SARS-CoV-2 variants of concern (VOCs), namely B.1.617.2 (delta) and B.1.1.529 (omicron), using an ELISA-based surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of the interaction between viral receptor binding domain (RBD) and the angiotensin-converting enzyme 2 (ACE2) protein [27]. Furthermore, a cPassTM SARS-CoV-2 neutralizing antibody detection kit (GenScript Biotech, Piscataway, NJ, USA) was used for all strains following the manufacturer's instructions. Recombinant RBDs from B.1.617.2 (containing L452R and T478K) and B.1.1.529 (containing N501Y, E484A, K417N, and D614G) were also used with this kit. The ability of a serum to inhibit binding between RBD and ACE2 was calculated as a percentage as follows: $1 - (average OD of the sample / average OD of the negative control) X 100. A value <math display="inline">\geq 30\%$ was considered positive, indicating the presence of neutralizing antibodies. The lower limit of detection was established as 0% inhibition.

2.4.3 SARS-CoV-2 Stimulating IFN-□ Assay

The subset of participants' whole heparinized blood samples from the third booster group was taken at all time points on days 0, 14, 28, and 90 to assess the specific T-cell response. The heparinized whole blood sample was collected in a blood collection tube from QuantiFERON (QFN) SARS-CoV-2 RUO kit (QIAGEN, Hilden, Germany) following the manufacturer's instruction and incubated at 37°C for 21 to 24 hours and was then centrifuged for 15 minutes at 3500 g to harvest the plasma. This test is based on the in vitro stimulation of CD4+ and CD8+ lymphocytes in whole heparinized blood with a combination of specific SARS-CoV-2 antigens covering the S protein, followed by measurement in plasma of IFN- \Box production by ELISA. This assay consisted of two sets of SARS-CoV-2 S antigens. The Ag1 tube contained CD4+ epitopes derived from the S1 subunit (RBD), while the Ag2 tube contained CD4+ and CD8+ epitopes from S1 and S2. Furthermore, the plasma fraction was used to determine the concentration of IFN- \Box

(IU/mL) using QuantiFERON® ELISA. Absorbance was measured at 450 nm and calculated using IFN- \square standard curve using the QuantiFERON R&D Analysis Software. The seropositivity rate was calculated using IFN- \square levels from the stimulated tube minus the negative control tube. An IFN- \square level of \ge 0.15 IU/mL and \ge 25% of Nil were defined as a positive response against SARS-CoV-2, while the maximum limit was 10.0 IU/mL.

2.5 Statistical Analysis

The sample size was calculated using the G^* -power software version 3.1.9.6. Graphical representation and statistical analyses were performed using GraphPad Prism version 7.0 for Microsoft Windows. Categorical analyses of age and sex were performed using the chi-square test and Welch's ANOVA. IgG-specific RBDs were designated as geometric mean titers (GMT) with a 95% confidence interval (CI). Other parameters were presented as medians with interquartile ranges. Differences in antibody titers, percentage inhibition, and IU/mL minus nil between groups were calculated using the Kruskal–Wallis test or Wilcoxon signed rank test (nonparametric) multiple comparison adjustments. A p-value < 0.05 was considered to indicate statistical significance.

3. Results

3.1 Antibody responses against SARS-CoV-2 in the BBIBP-CorV primed group

The BBIBP-CorV primed group consisted of 21 male participants and 30 female participants. The average and median ages are 37.7 and 35.0, respectively. Ten participants were lost to follow-up during the study. The enrollment flow diagram is shown in Figure 1.




Figure 1 Study diagram for enrollment of participants in this study. Schematic depicting a total of 51 participants in the BBIBP-CorV primed group and 144 participants in the third boost group.

Total levels of RBD Ig and anti-RBD IgG at 30 days after two-dose vaccination in the BBIBP-CorV primed group showed a seropositivity rate of 97.8% and 93.6%, respectively. The maximum level of total RBD Ig and anti-RBD IgG was detected in all participants after completing two doses of BBIBP-CorV at 30 days, with GMT 42.8 U/mL and 50.0 BAU/mL, respectively. The waning of antibody titers was observed after 90 days of completed vaccination, as shown in Figure 2 and Supplementary Table S1.




Figure 2 Antibody responses against SARS-CoV-2 in the BBIBP-CorV primed group. **(a)** The total circulating RBD Ig of SARS-CoV-2 (U/mL), and **(b)** Circulating anti-RBD IgG of SARS-CoV-2 (BAU/mL). Lines represent GMTs. The dotted lines represent the cutoff titers; p < 0.01 (**).

3.2 Antibody responses against SARS-CoV-2 in the third boost group

In the third booster group, healthy participants who received two doses of BBIBP-CorV over 6 ± 1 months were separated into three groups to receive the additional doses with a viral vector or mRNA COVID-19 vaccine depending on the vaccine availability. None of the 144 enrolled participants had underlying disease or had well-controlled disease, were not immunocompromised, or were receiving treatment with ongoing immunosuppressive therapy. The baseline demographic characteristics of all participants in the three groups, namely those who received vaccines AZD1222 (n = 33, median age = 45.0 years), BNT162b2 (n = 56, median age = 40.0 years), and mRNA-1273 (n = 55, median age = 46.0 years) vaccines; the average age of the participants enrolled in each group was 42.27, 41.89, and 44.02 years, respectively. There were no significant differences in sex and age in each group. The enrollment flow diagram is shown in Figure 1.

The most common symptom induced by the third booster dose of the COVID-19 vaccine in three groups was injection site pain. The requested injection site and systemic adverse reactions were reported. The most common adverse effects at the injection site and systemic adverse reactions were myalgias, headache, and chilling. The incidence of total local and systemic symptoms in the AZD1222, BNT162b2 and mRNA-1273 groups are shown in Figure 3 and Supplementary Table S1. The third dose of AZD1222 has a significantly lower incidence of swelling than BNT162b2, and the mRNA-1273 vaccine while fever symptoms have a higher incidence, the remaining differences were not significant. Any adverse reactions resolved within a few days. After vaccination, no severe adverse events (SAEs) were observed in all third booster subgroups.





Figure 3 Reactogenicity of a booster dose of SARS-CoV-2 vaccines within 7 days after vaccination. Third booster subgroups: (a) AZD1222, (b) BNT162b2, and (c) mRNA-1273. The percentages of participants who recorded local, systemic, and adverse events are shown on the Y-axis. Fever was defined as mild: 38.0° C to < 38.5° C; moderate: 38.5° C to < 39.0° C; severe $\geq 39.0^{\circ}$ C. For local and systemic symptoms, the classification was classified as mild: easily tolerated with no limitation of regular activity; moderate: some limitation of daily activity; severe: unable to perform regular daily activity.

The antibody level before the booster in individuals from all third booster subgroups showed that the total RBD Ig and anti-RBD IgG levels at baseline were maintained at a low level, similar to the BBIBP-CorV primed group. After receiving the third dose, there was a substantial increase in the highest titers on day 14 and a slight decrease up to day 90, as shown in Figure 4 and Supplementary Table S1. Compared with the third booster group, AZD1222 achieved total RBD Ig and anti-RBD IgG levels that were significantly lower than those achieved with BNT162b2 or mRNA-1273.






Figure 4 Antibody responses to the SARS-CoV-2 assay in a third boost group. **(a)** The total RBD Ig circulating of SARS-CoV-2 (U/mL) and **(b)** The anti-RBD IgG circulating of SARS-CoV-2 (BAU/mL). Serum samples were obtained from participants who received the third dose with AZD1222 (green), BNT162b2 (red) or mRNA-1273 (blue). Lines represent GMTs (95% CI). The dotted lines represent the cutoff titers; p < 0.01 (***).

3.3 Surrogate virus neutralization test

The functionally binding antibody that may inhibit SARS-CoV-2 delta and omicron variants was evaluated by sVNT. According to Figure 5 and Supplementary Table S1, before the third dose vaccination, the median percentage of inhibition of participants who received BBIBP-CorV was less than 30.0% for the delta and omicron variants. In the comparison of neutralizing activities between the different third-dose platforms, the percentage inhibition against delta and omicron variants was achieved to the highest after booster on day 14. The median of neutralizing activities against the delta variant showed a 97.0% inhibition in the vaccination with the three vaccines studied. The median neutralizing activities against the omicron variant of the third dose with AZD1222, BNT162b2, and mRNA-1273 was a 49.8%, 67.4%, and 53.7%, respectively. On day 28, the percentage of inhibition against omicron variants decreased slightly to less than 30.0% on day 90, while the percentage of inhibition against delta variants was still higher than 90%. The neutralizing capacity of sera against the omicron variant in all third dose groups was lower than that of the delta variant. In addition, the third dose of AZD1222 vaccine recipients had no significant difference on the neutralizing activity against the delta variant with BNT162b2 and mRNA-1273 vaccine recipients but had a lower neutralizing activity against the omicron variant significantly (p-value < 0.01).

The correlation was plotted between the percentage of inhibition against the SARS-CoV-2 variants, total-RBD Ig, and anti-RBD IgG. The nonlinear regression, one-phase decay model, can predict immunogenicity titers to neutralize inhibition against delta and omicron variants in the third dose with the different platforms (Supplementary Figures S1 and S2).




Figure 5 Neutralization activities against SARS-CoV-2 variants B.1.617.2 (delta) and B.1.1.529 (omicron) measured by the Surrogate virus neutralization test (sVNT). The subset of serum samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273 (blue) were selected to test sVNT at baseline, 14-, 28- and 90-days after the booster dose. **(a)** Neutralizing activity against delta variants, and **(b)** neutralizing activity against omicron variants. The lines represent medians with interquartile ranges (IQR). The dotted lines represent the cutoff titers; p-value < 0.01 (***).

3.4 SARS-CoV-2 Stimulating IFN- \square CD4+/IFN- \square CD4+ and CD8+ T-cell response

The IFN- \square response to SARS-CoV-2 IFN- \square CD4+/IFN- \square CD4+ and CD8+ were evaluated, as shown in Figure 6 and Supplementary Table S1. Interestingly, a potential antiviral-induced IFN- \square stimulation of T cells was notably observed. The marked individual difference in terms of IFN- \square release induced by IFN- \square CD4+/IFN- \square CD4+ and CD8+ ranged from 0.0 IU/mL to 10.0 IU/mL. In terms of the serological response, the seropositivity rates for the IFN- \square CD4+/IFN- \square CD4+ and CD8+ levels observed in most participants after the booster dose 14 days were 67.9%/82.1% for AZD1222, 83.3%/93.3% for BNT162b2, and 86.2%/93.1% for mRNA-1273. The production of IFN- \square by T-cells was decreased on days 28 and 90, consistent with the total RBD Ig and anti-RBD IgG levels. All booster vaccines showed that humoral immunity also developed cellular immunity. In contrast, both BNT162b2 and mRNA-1273 vaccines can stimulate robust antigen-specific T-cell responses after 14 days with especially high levels of IFN- \square . There was a good correlation between the results for IFN- \square CD4+/IFN- \square CD4+ and CD8+ (Spearman correlation coefficient, p-value < 0.01).




Figure 6 SARS-CoV-2-stimulating IFN- \square assay. The subset of heparinized samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), the BNT162b2 (red), or the mRNA-1273 (blue) were stimulated by CD4+ epitope derived from RBD (Ag1), and CD4+/CD8+ epitope derived from S1 and S2 subunits (Ag2) and incubated in a QFN blood collection tube for at least 21 hours. QFN IFN- \square ELISA evaluated the plasma fraction on days 0, 14, 28, and 90. (a) The IFN- \square produced by CD4+ specific Ag1, and (b) The IFN- \square produced by CD4+ and CD8+ specific Ag2. Lines represent medians (IQR). The dotted lines represent cutoff titers. Statistical analysis was performed using the Wilcoxon signed-rank test (two-tailed); p-value < 0.05 (*).

4. Discussion

The BBIBP-CorV vaccine is a highly valuable tool against COVID-19, due to its less stringent storage and shipment requirements, which differs from mRNA-based vaccines. The BBIBP-CorV vaccine has been approved for use in more than 45 countries around the world, and the interim results of the phase 3 trials indicated a 78.1% efficacy in preventing the ancestral variant [28]. Our data showed that immunogenicity could be detected after two doses of the BBIBP-CorV vaccine at 30 days, and the seropositivity rate of total RBD Ig and anti-RBD IgG was 97.8% and 93.6%, respectively. The magnitudes of the total RBD Ig and anti-RBD IgG responses were highest (GMT 42.8 U/mL, and 50.0 BAU/mL, respectively) in individuals 30 days after having completed two doses of BBIBP-CorV vaccine and slightly decreased and maintain at a low level until 90 days to similar levels as the baseline of the third dose group who received over 6 ± 1 months of two doses of BBIBP-CorV vaccine. These results were in line with a previous study reporting that on day 18 after vaccination with the BBIBP-CorV vaccine, more than half of the participants showed negative results for the IgG anti-spike protein antibody test and indicates that the BBIBP-CorV vaccine does not produce a sufficient immune response in most vaccinated individuals [6].

With regard to the side effects of the third dose, the previous studies [29,30] showed that the most reported adverse effects of AZD1222 were pain and tenderness at the injection site, fatigue, and headache. Side effects started on the first day after vaccination and lasted 1 to 3 days, while the most common side effects for BNT162b2 and mRNA-1273 were pain at the injection site, headaches, fever, flu-like symptoms and fatigue. Although postvaccination side effects are the same for all vaccines, the number and severity of these side effects differ significantly according to the type of vaccine. In this study, an incidence rate of injection site and systemic reactions was reported within 7 days after boost vaccination, all adverse symptoms were mild in severity and mostly

transient. The results suggest that a third booster vaccination in healthy adults aged over 18 years is safe, and these results may help support booster vaccination strategies to be administered in the future [31].

Studies of the third dose of COVID-19 vaccination reported the effectiveness of reducing risk in symptomatic infection and hospitalization rates compared to two doses of vaccination [15,19,22]. Therefore, for the general population, vaccination is necessary. Furthermore, heterologous booster doses (two prime doses with inactivate or viral vector vaccine and the third dose with mRNA vaccine) appear to induce higher levels of immune response than homologous booster doses, suggesting that heterologous immunization could be considered an alternative to homologous booster doses for immunization programs [22,32,33]. To assess the immunogenicity of a booster vaccination, our study found that a third booster dose with heterologous booster immunization of AZD1222, BNT162b2, and mRNA-1273 showed a high titer of total RBD Ig and anti-RBD IgG compared to before the third booster. Immunogenicity and neutralizing antibody titers increased significantly on day 14. After 28 days from the third booster dose, the immunogenicity, and neutralizing titers continuously decreased until day 90. In correlation with previous studies, after previous priming vaccination with two doses of CoronaVac, the effectiveness against delta and omicron variants of a third booster shot of CoronaVac, AZD1222, and BNT162b2 14 days after vaccination was 56-80%, 56-90% and 56-93%, respectively [14,34]. Neutralizing antibodies are the most important parameter for measuring the immune response to prevent disease and reinfections. Although neutralizing antibodies are difficult to investigate in routine laboratories, the level of anti-SARS-CoV-2 IgG is indicative. Previous studies found that neutralizing antibodies and anti-SARS-CoV-2 IgG titers are compatible. The level of total anti-RBD antibodies was strongly correlated with the neutralizing antibodies titers of SARS-CoV-2, especially against the ancestral strain [35,36]. This study showed that the titers of total RBD Ig and anti-RBD IgG are correlated with the neutralizing antibody titers against delta and omicron variants. Such results supported the concept that a higher immune response would provide better neutralizing antibodies in the real world.

For the IFN-□ response, previous studies have reported that the third dose of inactivated SARS-CoV-2 vaccine could generate SARS-CoV-2 specific CD4+ and CD8+ T cells and elicit B cell responses by antibody evolution [37]. This study observed seropositivity rates for the IFN-□ CD4+/IFN-□ CD4+ and CD8+ levels in most participants after the booster dose of 14 days, and a significant decrease in IFN-□ production T cells after boosting the dose for 14 days, limiting the efficacy of the vaccines. This result is similar to that of a previous report [37] and suggests that a second dose is developing an effective immune response and further boosters may be needed to increase and retain the effectiveness of the vaccine in adults. Whether enhanced B and T cell responses could lead to greater protection efficacy is one of the key questions concerning current boosting strategies. As a result, a third dose of the vaccine after six months, even a viral vector or mRNA vaccine, has published new guidelines making it mandatory to get a booster. However, to generalize for a larger population, more data are needed in the future.

The limitations of the current study include the limit of detection of the sVNT assay. Most individuals receiving a booster dose achieved an elevation in antibody levels that was greater than the upper limit of detection. This method may not reflect the actual neutralizing antibody level. Furthermore, the lost follow-up participants due to breakthrough infection or lost contact during the follow-up period may not reflect the actual values at each time point.

In conclusion, a third dose heterologous regimen, two initial doses of BBIBP-CorV vaccines followed by a viral vector or mRNA vaccine induced a robust immunological

 response. This study found that a two-dose schedule generated good immune memory. However, immunogenicity titers decreased to near or below the lower limit of the seropositivity rate over time. A third dose is given over 6 ± 1 month after the second dose of BBIBP-CorV was highly effective in re-calling a specific SARS-CoV-2 immune response, leading to a significant rebound in antibody levels. This approach would make it possible to optimize the third available booster dose of vaccines without increasing the risk of infection and allowing a faster expansion of vaccination coverage.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1,

Figure S1: Correlation between the percentage of inhibition against the SARS-CoV-2 variants and the total RBD Ig levels. The subset of serum samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273 (blue) were plotted with a non-linear regression curve. (a) AZD1222 against the delta variant, (b) AZD1222 against the omicron variant (c) BNT162b2 against the delta variant, (d) BNT162b2 against the omicron variant, (e) mRNA-1273 against the delta variant and (f) mRNA-1273 against the omicron variant.

Figure S2 The correlation between the percentage of inhibition against SARS-CoV-2 variants and anti-RBD IgG levels. The subset of serum samples was obtained from a third booster group. Participants who received the third dose of AZD1222 (green), BNT162b2 (red), or mRNA-1273 (blue) were plotted with a non-linear regression curve. (a) AZD1222 against delta variant, (b) AZD1222 against the omicron variant, (c) BNT162b2 against the delta variant, (d) BNT162b2 against the omicron variant, (e) mRNA-1273 against the delta variant, (f) mRNA-1273 against the omicron variant.

Table S1 The demographic characteristics and laboratory tests value of participants enrolled in this study.

Author Contributions: Conceptualization, J.C., N.S., S.K., S.A., R.Y., P.N., N.W., N.S., and Y.P.; Methodology, J.C., N.S., S.K., S.A., R.Y., P.V., S.K., L.W., D.S., T.T., T.T., C.A.; Software, J.C., N.S., S.K., S.A., R.Y.; Validation, N.W., N.S.; Formal analysis, J.C., N.S., S.K., S.A.; Investigation, J.C., N.S., S.K., S.A., R.Y.; Resources, N.W., N.S., and Y.P.; Data curation, J.C., S.K.; Writing original draft preparation, J.C.; Writing review and editing, J.C., N.W., and Y.P.; Visualization, J.C., N.S., S.K.; Supervision, N.S., and Y.P.; Project administration, P.N., D.S., T.T.; Funding acquisition, Y.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a Health Systems Research Institute (HSRI), the National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology of Chulalongkorn University/King Chulalongkorn Memorial Hospital (GCE 59-009-30-005), the Second Century Fund (C2F), Chulalongkorn University to Jira Chansaenroj and MK Restaurant Group Public Company

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 192/64, approval date 18 March 2021 and 546/64, approval date 20 July 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper

Data Availability Statement. The authors confirm that the data supporting the findings of this study are available within the article.

Acknowledgments: We greatly appreciate all participants for helping and supporting this study. We thank all staff from the Center of Excellence in Clinical Virology, Faculty of Medicine,

458 Chulalongkorn University, for their help with the experiment. We also thank the Ministry of Public
459 Health and Chulabhorn Royal Academy for providing the vaccines for this study.

Conflicts of Interest: The authors declare no conflict of interest.

460 461

462

References

- 463 1. Weiss, P.; Murdoch, D.R. Clinical course and mortality risk of severe COVID-19. Lancet 2020, 395, 1014-1015,
- 464 doi:10.1016/S0140-6736(20)30633-4.
- 465 2. Del Rio, C.; Malani, P.N.; Omer, S.B. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA 2021, 326, 1001-1002,
- 466 doi:10.1001/jama.2021.14811.
- 467 3. Mallapaty, S. China's COVID vaccines have been crucial now immunity is waning. Nature 2021, 598, 398-399, doi:10.1038/d41586-021-02796-w.
- 468 4. Al Kaabi, N.; Zhang, Y.; Xia, S.; Yang, Y.; Al Qahtani, M.M.; Abdulrazzaq, N.; Al Nusair, M.; Hassany, M.; Jawad, J.S.; Abdalla, J.; et al. Effect of 2
- 469 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 2021, 326, 35-45,
- 470 doi:10.1001/jama.2021.8565.
- 471 5. Wang, H.; Zhang, Y.; Huang, B.; Deng, W.; Quan, Y.; Wang, W.; Xu, W.; Zhao, Y.; Li, N.; Zhang, J.; et al. Development of an Inactivated Vaccine
- 472 Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell 2020, 182, 713-721 e719, doi:10.1016/j.cell.2020.06.008.
- 473 6. Elgendy, M.O.; El-Gendy, A.O.; Alzarea, A.I.; Mahmoud, S.; Alqahtani, S.S.; Fahmy, A.M.; El-Seedi, H.R.; Sayed, A.M.; Alatawi, A.D.;
- 474 Abdelrahim, M.E.A.; et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines (Basel) 2021, 10,
- 475 doi:10.3390/vaccines10010018.
- 476 7. Xia, S.; Zhang, Y.; Wang, Y.; Wang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated
- 477 SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021, 21, 39-51,
- 478 doi:10.1016/S1473-3099(20)30831-8.
- 479 8. Sreepadmanabh, M.; Sahu, A.K.; Chande, A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. J Biosci
- **2020**, 45.
- 481 9. Elgendy, M.O.; Abdelrahim, M.E.A. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J Med Virol 2021, 93,
- 482 6535-6543, doi:10.1002/jmv.27199.
- 483 10. Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al
- 484 Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021, 385, e83,
- 485 doi:10.1056/NEJMoa2114114.
- 486 11. Madhi, S.A.; Baillie, V.; Cutland, C.L.; Voysey, M.; Koen, A.L.; Fairlie, L.; Padayachee, S.D.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al.
- 487 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021, 384, 1885-1898, doi:10.1056/NEJMoa2102214.
- 488 12. Ismail AlHosani, F.; Eduardo Stanciole, A.; Aden, B.; Timoshkin, A.; Najim, O.; Abbas Zaher, W.; AlSayedsaleh AlDhaheri, F.; Al Mazrouie,
- 489 S.; Rizvi, T.A.; Mustafa, F. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Re-
- sults from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine 2022, 40, 2003-2010,
- 491 doi:10.1016/j.vaccine.2022.02.039.
- 492 13. Guo, Y.; Han, J.; Zhang, Y.; He, J.; Yu, W.; Zhang, X.; Wu, J.; Zhang, S.; Kong, Y.; Guo, Y.; et al. SARS-CoV-2 Omicron Variant: Epidemiolog-
- 493 ical Features, Biological Characteristics, and Clinical Significance. Front Immunol 2022, 13, 877101, doi:10.3389/fimmu.2022.877101.
- 494 14. Costa Clemens, S.A.; Weckx, L.; Clemens, R.; Almeida Mendes, A.V.; Ramos Souza, A.; Silveira, M.B.V.; da Guarda, S.N.F.; de Nobrega,
- 495 M.M.; de Moraes Pinto, M.I.; Gonzalez, I.G.S.; et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two
- doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022, 399, 521-529,
- 497 doi:10.1016/S0140-6736(22)00094-0.
- 498 15. Accorsi, E.K.; Britton, A.; Fleming-Dutra, K.E.; Smith, Z.R.; Shang, N.; Derado, G.; Miller, J.; Schrag, S.J.; Verani, J.R. Association Between 3
- 499 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 2022, 327,
- 500 639-651, doi:10.1001/jama.2022.0470.

- 501 16. Thompson, M.G.; Natarajan, K.; Irving, S.A.; Rowley, E.A.; Griggs, E.P.; Gaglani, M.; Klein, N.P.; Grannis, S.J.; DeSilva, M.B.; Stenehjem, E.;
- 502 et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
- 503 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January
- 504 2022. MMWR Morb Mortal Wkly Rep 2022, 71, 139-145, doi:10.15585/mmwr.mm7104e3.
- 505 17. Guo, W.; Duan, K.; Zhang, Y.; Yuan, Z.; Zhang, Y.B.; Wang, Z.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; et al. Safety and immunogenicity of an
- 506 inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.
- 507 EClinical Medicine 2021, 38, 101010, doi:10.1016/j.eclinm.2021.101010.
- 508 18. Zhu, F.; Jin, P.; Zhu, T.; Wang, W.; Ye, H.; Pan, H.; Hou, L.; Li, J.; Wang, X.; Wu, S.; et al. Safety and immunogenicity of a recombinant ade-
- 509 novirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a random-
- 510 ised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis 2021, doi:10.1093/cid/ciab845.
- 511 19. Zuo, F.; Abolhassani, H.; Du, L.; Piralla, A.; Bertoglio, F.; de Campos-Mata, L.; Wan, H.; Schubert, M.; Cassaniti, I.; Wang, Y.; et al. Heterolo-
- 512 gous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat
- 513 Commun **2022**, 13, 2670, doi:10.1038/s41467-022-30340-5.
- 514 20. Abu-Raddad, L.J.; Chemaitelly, H.; Ayoub, H.H.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Tang, P.; Hasan, M.R.; Coyle, P.; Al
- Kanaani, Z.; et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA
- 516 **2021**, 326, 1930-1939, doi:10.1001/jama.2021.19623.
- 517 21. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al.
- 518 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med 2021, 385, 1393-1400, doi:10.1056/NEJMoa2114255.
- 519 22. Matula, Z.; Gonczi, M.; Beko, G.; Kadar, B.; Ajzner, E.; Uher, F.; Valyi-Nagy, I. Antibody and T Cell Responses against SARS-CoV-2 Elicited
- 520 by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vac-
- cination Strategy. Vaccines (Basel) 2022, 10, doi:10.3390/vaccines10040539.
- 522 23. Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; Sproule, S.; Robb, M.L.; Corey, L.; Neuzil, K.M.; Hahn, W.; Hunt, J.; Mulligan, M.J.; et al. Phase 3
- 523 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021, 385, 2348-2360, doi:10.1056/NEJMoa2105290.
- 24. Jackson, L.A.; Anderson, E.J.; Rouphael, N.G.; Roberts, P.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.;
- 525 Stevens, L.J.; et al. An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med 2020, 383, 1920-1931, doi:10.1056/NEJMoa2022483.
- 526 25. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al.
- 527 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl | Med 2020, 383, 2603-2615, doi:10.1056/NEJMoa2034577.
- 528 26. Yorsaeng, R.; Suntronwong, N.; Phowatthanasathian, H.; Assawakosri, S.; Kanokudom, S.; Thongmee, T.; Vichaiwattana, P.; Auphimai, C.;
- Wongsris ang, L.; Srimuan, D.; et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vac-
- 530 cines in healthy adults. Vaccine 2022, 40, 524-530, doi:10.1016/j.vaccine.2021.11.083.
- Tan, C.W.; Chia, W.N.; Qin, X.; Liu, P.; Chen, M.I.; Tiu, C.; Hu, Z.; Chen, V.C.; Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus
- 532 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020, 38, 1073-1078,
- 533 doi:10.1038/s41587-020-0631-z.
- 534 28. Cheng, Z.J.; Huang, H.; Zheng, P.; Xue, M.; Ma, J.; Zhan, Z.; Gan, H.; Zeng, Y.; Lin, R.; Li, S.; et al. Humoral immune response of BBIBP
- 535 COVID-19 vaccination before and after the booster immunization. Allergy 2022, doi:10.1111/all.15271.
- 536 29. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi,
- 537 N.; et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study.
- 538 Int J Gen Med 2021, 14, 1389-1401, doi:10.2147/IJGM.S310497.
- 539 30. Solomon, Y.; Eshete, T.; Mekasha, B.; Assefa, W. COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine
- Among Health Professionals in Low-Income Country: Ethiopia. J Multidiscip Healthc 2021, 14, 2577-2585, doi:10.2147/JMDH.S331140.

- 541 31. Hatmal, M.M.; Al-Hatamleh, M.A.I.; Olaimat, A.N.; Hatmal, M.; Alhaj-Qasem, D.M.; Olaimat, T.M.; Mohamud, R. Side Effects and Percep-
- 542 tions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity
- of Side Effects. Vaccines (Basel) 2021, 9, doi:10.3390/vaccines9060556.
- 544 32. Barros-Martins, J.; Hammerschmidt, S.I.; Cossmann, A.; Odak, I.; Stankov, M.V.; Morillas Ramos, G.; Dopfer-Jablonka, A.; Heidemann, A.;
- 545 Ritter, C.; Friedrichsen, M.; et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1
- 546 nCoV-19/BNT162b2 vaccination. Nat Med 2021, 27, 1525-1529, doi:10.1038/s41591-021-01449-9.
- 547 33. Borobia, A.M.; Carcas, A.J.; Perez-Olmeda, M.; Castano, L.; Bertran, M.J.; Garcia-Perez, J.; Campins, M.; Portoles, A.; Gonzalez-Perez, M.;
- 548 Garcia Morales, M.T.; et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multi-
- 549 centre, open-label, randomised, controlled, phase 2 trial. Lancet 2021, 398, 121-130, doi:10.1016/S0140-6736(21)01420-3.
- 550 34. Ai, J.; Zhang, Y.; Zhang, H.; Zhang, Q.; Fu, Z.; Lin, K.; Song, J.; Zhao, Y.; Fan, M.; Wang, H.; et al. Safety and immunogenicity of a third-dose
- 551 homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. Emerg Microbes Infect 2022, 11, 639-647,
- 552 doi:10.1080/22221751.2022.2025746.
- 553 35. Kaygusuz, S.; Korukluoglu, G.; Cosgun, Y.; Sahin, O.; Arslan, F. Investigation and long-term monitoring of the presence of neutralizing an-
- 554 tibody in patients with COVID-19 disease of different clinical severity. J Med Virol 2022, doi:10.1002/jmv.27751.
- 555 36. Sanchez-Sendra, B.; Albert, E.; Zulaica, J.; Torres, I.; Gimenez, E.; Botija, P.; Beltran, M.J.; Rodado, C.; Geller, R.; Navarro, D. Neutralizing
- antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci Rep 2022, 12, 3788,
- 557 doi:10.1038/s41598-022-07849-2.

- 558 37. Liu, Y.; Zeng, Q.; Deng, C.; Li, M.; Li, L.; Liu, D.; Liu, M.; Ruan, X.; Mei, J.; Mo, R.; et al. Robust induction of B cell and T cell responses by a
- 559 third dose of inactivated SARS-CoV-2 vaccine. Cell Discov 2022, 8, 10, doi:10.1038/s41421-022-00373-7.

